Abnormal Uterine Bleeding (AUB)

Abnormal Uterine Bleeding (AUB)

Abnormal uterine bleeding is defined as menstrual blood loss (MBL) that interferes with physical, social, and mental quality of life, irrespective of the regularity frequency, or duration (NICE)

Heavy menstrual bleeding is the most common cause of iron deficiency anaemia. 20% of women complain of heavy menstrual bleeding. Perception of heavy menstrual bleeding remains unreliable since 50% of these women have a normal amount of blood loss when investigated.

Non-menstrual bleeding (postcoital, intermenstrual or post-menopausal bleeding) always warrants further investigation and early referral to a gynaecologist.

Normal vs Abnormal parameters for menstrual blood loss

ParameterNormal RangeNota bene
Menarche10 – 16 years (mean age 13)Abnormal if the thickness is out of phase or exceeds 16 mm in secretory phase
Cycle Frequency21–35 days<21 is polymenorrhoea while >35 days is oligomenorrhoea
Bleeding Duration2–7 days> 7 days suggest heavy menstrual bleeding
MBL Volume5–80 mL/cycle>80 mL is heavy menstrual bleeding
Cycle RegularityVariation < 9 daysVariation ≥ 9 days
Endometrial thickness (pre-menopausal)6 – 12 mmIt can be up to 8 mm if there is hormonal replacement therapy
Endometrial thickness (post-menopausal bleeding)< 4 mmCan be up to 8 mm if there is hormonal replacement therapy

FIGO Classification of Abnormal Uterine Bleeding(PALM-COEIN)

Structural Causes (PALM)

AcronymDescription
PPolyps (AUB-P)
AAdenomyosis (AUB-A)
LLeiomyoma (AUB-L; submucosal most relevant)
MMalignancy or hyperplasia (AUB-M)

Non-Structural Causes (COEIN)

AcronymDescription
CCoagulopathy (AUB-C; e.g. von Willebrand disease)
OOvulatory dysfunction (AUB-O; commonly anovulation)
EEndometrial (AUB-E; primary disorder)
IIatrogenic (AUB-I; e.g. anticoagulants, IUD)
NNot classified e.g. niche, arteriovenous malformation
FIGO Classification of Abnormal Uterine Bleeding
  • Some terms used to describe abnormal uterine bleeding
    • Heavy menstrual bleeding (HMB)
    • Intermenstrual bleeding (IMB)
    • Postcoital bleeding
    • Postmenopausal bleeding
    • Oligomenorrhoea and amenorrhoea
    • Dysfunctional uterine bleeding
    • Irregular menstrual cycle
  • Pathogenesis of uterine bleeding
    • Fibrinolytic Pathway Dysregulation:
      • Progesterone controls fibrinolysis.
      • Increased Tissue plasminogen activator (tPA) > PAI-1 → Excessive clot breakdown
    • Prostaglandin Imbalance:
      • Increased PGE₂ (vasodilatory) vs. reduced PGF₂α (vasoconstrictive) → Increased blood flow
    • Endometrial Inflammation:
      • ↑ TNF-α, IL-1β → disrupted vascular integrity
  • Patient History
    • Adolescents:
      • AUB-O most common – infrequent cycles, painless prolonged or HMB
      • Rule out coagulopathy (e.g., VWD in 20%) – HMB since menarche
    • Perimenopause:
      • Exclude endometrial hyperplasia/cancer first.
    • HMB Indicators:
      • Soaking >2 pads/hour
      • Changing pads every 3 hours
      • More than 20 pads used in 1 cycle
      • Passing clots > 1 inch
      • Needs extra pads at night
      • Bleeding soils clothing or bedsheets
      • Flow lasts > 7 days
      • Signs and symptoms of anaemia
    • Menstrual Patterns:
      • Cyclical HMB = AUB-L (submucosal), AUB-A, AUB-C, AUB-E
      • Cyclical IMB = AUB-P (benign or malignant)
      • Acyclical HMB = Malignancy
      • Acyclical IMB = AUB-O
      • IMB and Post-coital bleeding = exclude malignancy and polyps
    • Red Flags:
      • Postmenopausal bleeding
      • Weight loss
      • Family history of malignancy (Lynch syndrome/BRCA)
  • Investigations
    • B-hCG: rule out pregnancy
    • TVUS: to measure endometrial thickness and identify structural lesions
      • Normal or thick endometrium = hyperestrogenic (hyperplasia with or without atypial – will respond to progesterone)
      • Thin endometrium = low estrogen level (less risk of malignancy, may not respond to progesterone initially)
    • Complete blood count and iron panel: assess for iron deficiency anaemia
    • Endometrial biopsy: for high-risk patients – if age >45 or unopposed estrogen exposure
    • Hysteroscopy: to identify for focal lesions
    • Coagulation panel
  • Medical treatment
    • Keep a menstrual calendar
    • NSAIDS and Tranexamic or mefanamic acid for 5 days: first-line. Controls bleeding in 60 – 80% of patients
      • Tranexamic acid reduces MBL by 40 – 50%
      • NSAIDs reduce bleeding by 30%
    • High-Dose Progestin e.g. Norethisterone for 10 days to stabilize the endometrium
    • Combined oral contraceptive pills: 80% of patients respond to COCs
    • Hormonal IUD (MIrena/LNG-IUD): most effective hormonal agent. Reduces bleeding by 95%
  • Surgical treatment
    • Temporary Balloon tamponade
    • Hysteroscopic resection of polyps or submucosal fibroids
    • Endometrial ablation for refracotry AUB-E (contraindicated if future fertility is desired)
    • Hysterectomy

Long-term treatment

CauseTreatment
AUB-OCyclic progestins/COCs
AUB-LMyomectomy/Uterine artery embolization
AUB-ALNG-IUS/endometrial ablation
AUB-CDesmopressin (for VWD)
Dr. Jeffrey Kalei
Dr. Jeffrey Kalei

Creator and illustrator at Hyperexcision. Interested in emergency room medicine. I have a passion for medical education and drawing.

Articles: 462

Post Discussion

Your email address will not be published. Required fields are marked *